Advanced Bionics

Implantable electrostimulation devices.

An estimated two million Americans who are profoundly deaf cannot be helped with a hearing aid, which merely amplifies sound, because they suffer from sensorineural deafness (an absence of hair cells in the inner ear which convert sound waves to electrical signals). Cochlear implants can help this population by bypassing hair cells to send electrical signals directly to the auditory nerve. Advanced Bionics’ Clarion, the only US-made implantable cochlear device, is sold in the US and 28 countries. It consists of an implant that has 16 electrodes within the cochlea and an external speech processor box connected to a behind-the-ear headpiece containing an implanted receiver. Clarionsends sound waves directly to the system’s speech processor which converts them to electrical impulses that directly stimulate the auditory nerve. FDA-approved for adults in March 1996, Clarion has enabled over 60% of the post-lingually deaf adults who have tested the device to communicate without reading lips and to use the telephone.

In an $85 million worldwide market, Clarioncompetes with cochlear implants made by Australian-based Cochlear Ltd. and Med-EL, an Austrian company...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By 

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.